Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride
The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterob...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Castanheira, Mariana [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications - Rodrigues, Jéssica S. ELSEVIER, 2023, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:89 ; year:2017 ; number:4 ; pages:305-309 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.diagmicrobio.2017.08.011 |
|---|
| Katalog-ID: |
ELV041000382 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV041000382 | ||
| 003 | DE-627 | ||
| 005 | 20230625233430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180725s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2017.08.011 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000033.pica |
| 035 | |a (DE-627)ELV041000382 | ||
| 035 | |a (ELSEVIER)S0732-8893(17)30263-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.80 |2 bkl | ||
| 084 | |a 58.30 |2 bkl | ||
| 100 | 1 | |a Castanheira, Mariana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. | ||
| 520 | |a The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. | ||
| 700 | 1 | |a Duncan, Leonard R. |4 oth | |
| 700 | 1 | |a Rhomberg, Paul R. |4 oth | |
| 700 | 1 | |a Sader, Helio S. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Rodrigues, Jéssica S. ELSEVIER |t Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |d 2023 |g Amsterdam [u.a.] |w (DE-627)ELV009877355 |
| 773 | 1 | 8 | |g volume:89 |g year:2017 |g number:4 |g pages:305-309 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.diagmicrobio.2017.08.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.80 |j Makromolekulare Chemie |q VZ |
| 936 | b | k | |a 58.30 |j Biotechnologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 89 |j 2017 |e 4 |h 305-309 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m c mc |
|---|---|
| matchkey_str |
castanheiramarianaduncanleonardrrhomberg:2017----:nacdciiyfeeieaoatmc48aantppouigneoatraeehnetdneispl |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
35.80 58.30 |
| publishDate |
2017 |
| allfields |
10.1016/j.diagmicrobio.2017.08.011 doi GBV00000000000033.pica (DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Castanheira, Mariana verfasserin aut Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. Duncan, Leonard R. oth Rhomberg, Paul R. oth Sader, Helio S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:89 year:2017 number:4 pages:305-309 extent:5 https://doi.org/10.1016/j.diagmicrobio.2017.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 89 2017 4 305-309 5 045F 610 |
| spelling |
10.1016/j.diagmicrobio.2017.08.011 doi GBV00000000000033.pica (DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Castanheira, Mariana verfasserin aut Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. Duncan, Leonard R. oth Rhomberg, Paul R. oth Sader, Helio S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:89 year:2017 number:4 pages:305-309 extent:5 https://doi.org/10.1016/j.diagmicrobio.2017.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 89 2017 4 305-309 5 045F 610 |
| allfields_unstemmed |
10.1016/j.diagmicrobio.2017.08.011 doi GBV00000000000033.pica (DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Castanheira, Mariana verfasserin aut Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. Duncan, Leonard R. oth Rhomberg, Paul R. oth Sader, Helio S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:89 year:2017 number:4 pages:305-309 extent:5 https://doi.org/10.1016/j.diagmicrobio.2017.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 89 2017 4 305-309 5 045F 610 |
| allfieldsGer |
10.1016/j.diagmicrobio.2017.08.011 doi GBV00000000000033.pica (DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Castanheira, Mariana verfasserin aut Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. Duncan, Leonard R. oth Rhomberg, Paul R. oth Sader, Helio S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:89 year:2017 number:4 pages:305-309 extent:5 https://doi.org/10.1016/j.diagmicrobio.2017.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 89 2017 4 305-309 5 045F 610 |
| allfieldsSound |
10.1016/j.diagmicrobio.2017.08.011 doi GBV00000000000033.pica (DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Castanheira, Mariana verfasserin aut Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride 2017transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. Duncan, Leonard R. oth Rhomberg, Paul R. oth Sader, Helio S. oth Enthalten in Elsevier Science Rodrigues, Jéssica S. ELSEVIER Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications 2023 Amsterdam [u.a.] (DE-627)ELV009877355 volume:89 year:2017 number:4 pages:305-309 extent:5 https://doi.org/10.1016/j.diagmicrobio.2017.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.80 Makromolekulare Chemie VZ 58.30 Biotechnologie VZ AR 89 2017 4 305-309 5 045F 610 |
| language |
English |
| source |
Enthalten in Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications Amsterdam [u.a.] volume:89 year:2017 number:4 pages:305-309 extent:5 |
| sourceStr |
Enthalten in Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications Amsterdam [u.a.] volume:89 year:2017 number:4 pages:305-309 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Makromolekulare Chemie Biotechnologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |
| authorswithroles_txt_mv |
Castanheira, Mariana @@aut@@ Duncan, Leonard R. @@oth@@ Rhomberg, Paul R. @@oth@@ Sader, Helio S. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009877355 |
| dewey-sort |
3610 |
| id |
ELV041000382 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041000382</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625233430.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diagmicrobio.2017.08.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000033.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041000382</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0732-8893(17)30263-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castanheira, Mariana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duncan, Leonard R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rhomberg, Paul R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sader, Helio S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Rodrigues, Jéssica S. ELSEVIER</subfield><subfield code="t">Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009877355</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:89</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:305-309</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diagmicrobio.2017.08.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">89</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">305-309</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Castanheira, Mariana |
| spellingShingle |
Castanheira, Mariana ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30 Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| authorStr |
Castanheira, Mariana |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009877355 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| topic |
ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30 |
| topic_unstemmed |
ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30 |
| topic_browse |
ddc 610 ddc 540 fid BIODIV bkl 35.80 bkl 58.30 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l r d lr lrd p r r pr prr h s s hs hss |
| hierarchy_parent_title |
Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |
| hierarchy_parent_id |
ELV009877355 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 570 - Life sciences; biology |
| hierarchy_top_title |
Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009877355 |
| title |
Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| ctrlnum |
(DE-627)ELV041000382 (ELSEVIER)S0732-8893(17)30263-8 |
| title_full |
Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| author_sort |
Castanheira, Mariana |
| journal |
Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |
| journalStr |
Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
305 |
| author_browse |
Castanheira, Mariana |
| container_volume |
89 |
| physical |
5 |
| class |
610 610 DE-600 540 570 VZ BIODIV DE-30 fid 35.80 bkl 58.30 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Castanheira, Mariana |
| doi_str_mv |
10.1016/j.diagmicrobio.2017.08.011 |
| dewey-full |
610 540 570 |
| title_sort |
enhanced activity of cefepime–tazobactam (wck 4282) against kpc-producing enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| title_auth |
Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| abstract |
The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. |
| abstractGer |
The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. |
| abstract_unstemmed |
The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride |
| url |
https://doi.org/10.1016/j.diagmicrobio.2017.08.011 |
| remote_bool |
true |
| author2 |
Duncan, Leonard R. Rhomberg, Paul R. Sader, Helio S. |
| author2Str |
Duncan, Leonard R. Rhomberg, Paul R. Sader, Helio S. |
| ppnlink |
ELV009877355 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.diagmicrobio.2017.08.011 |
| up_date |
2024-07-06T18:57:41.419Z |
| _version_ |
1803857178309689344 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041000382</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625233430.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diagmicrobio.2017.08.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000033.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041000382</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0732-8893(17)30263-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castanheira, Mariana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of this study was to evaluate the in vitro activity of cefepime–tazobactam cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 0.85% sodium chloride (NaCl) or 50% human serum in comparison to standard CA-MHB when testing KPC-producing isolates. A total of 209 contemporary Enterobacteriaceae clinical isolates carrying bla KPC were tested, and cefepime–tazobactam (tazobactam at fixed 8mg/L) activity was enhanced 2-fold when tested in CA-MHB supplemented with 0.85% NaCl or 50% human serum (MIC50/90, 8/32mg/L for both media) compared to standard CA-MHB (MIC50/90, 16/64mg/L). Cefepime–tazobactam at a concentration of ≤16mg/L, which is the pharmacokinetics/pharmacodynamics tentative susceptibility breakpoint based on a high dosing regimen of cefepime–tazobactam (2g–2g q8h 90-minute infusion), inhibited 79.4–80.4% of Enterobacteriaceae isolates carrying bla KPC in MHB supplemented with 0.85% NaCl or 50% human serum. A similar decrease in MIC values was observed when cefepime alone was tested against a subset of the isolates (n=54) in CA-MHB supplemented with 50% human serum or 0.85% NaCl; however, imipenem activity against these 54 organisms was similar or 2-fold higher in CA-MHB supplemented with 0.85% of NaCl (MIC50/90, 8/16mg/L) or with 50% human serum (MIC50 and MIC90, 16mg/L) compared standard CA-MHB (MIC50/90, 8/16mg/L). In summary, cefepime–tazobactam MIC values against Enterobacteriaceae isolates carrying bla KPC were consistently lower in media supplemented with human serum or NaCl, which better mimics physiological conditions. These results suggest that this carbapenem-sparing candidate agent has potential to be used to treat infections caused by KPC-producing Enterobacteriaceae.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duncan, Leonard R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rhomberg, Paul R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sader, Helio S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Rodrigues, Jéssica S. ELSEVIER</subfield><subfield code="t">Selected Kraft lignin fractions as precursor for carbon foam: Structure-performance correlation and electrochemical applications</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009877355</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:89</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:305-309</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diagmicrobio.2017.08.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.80</subfield><subfield code="j">Makromolekulare Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">89</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">305-309</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402194 |